Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Collins, R. Peto, S. MacMahon, P. Hebert, N.H. Fiebach, K.A. Eberlein, et al.
Blood pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
Lancet, 335 (1990), pp. 827-838
[2.]
L. Hansson.
The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension.
J Hypertens, 14 (1996), pp. 537-544
[3.]
C.J. Vaughan, A.M. Gotto, C.T. Basson.
The evolving role of statins in the management of atherosclerosis.
J Am Coll Cardiol, 35 (2000), pp. 1-10
[4.]
J.A. Staffa, J. Chang, L. Green.
Cerivastatin and reports of fatal rhabdomyolysis.
N Engl J Med, 346 (2002), pp. 539-540
[5.]
H.R. Davis Jr., K.K. Pula, K.B. Alton, R.E. Burrier, R.W. Watkins.
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors in dogs.
Metabolism, 50 (2001), pp. 1234-1241
[6.]
D. Hunninghake, W. Insull Jr., P. Toth, D. Davidson, J.M. Donovan, S.K. Burke.
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
Atherosclerosis, 158 (2001), pp. 407-416
[7.]
M.L. Kashyap, M.E. McGovern, K. Berra, J.R. Guyton, P.O. Kwiterovich, W.L. Harper, et al.
Long-term safety and efficacy of a once-daily niacin/ lovastatin formulation for patients with dyslipidemia.
Am J Cardiol, 89 (2002), pp. 672-678
[8.]
A. Faggiotto, R. Paoletti.
State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action.
Hypertension, 34 (1999), pp. 987-996
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.